past
month
novel
coronaviru
diseas
pandem
pose
mani
challeng
practic
phyicianssarcoidosi
patient
may
increas
risk
poor
outcom
death
infect
sever
reason
first
sarcoidosi
involv
lung
approxim
patient
mani
diminish
baselin
lung
function
reduc
pulmonari
reserv
develop
respiratori
failur
second
although
etiolog
sarcoidosi
unknown
postul
immunolog
dysfunct
dysregul
play
essenti
role
develop
diseas
third
africanamerican
race
mani
comorbid
associ
glucocorticoid
gc
therapi
hypertens
diabet
obes
identifi
center
diseas
control
independ
risk
factor
death
preval
sarcoidosi
cohort
final
pertin
treat
clinician
immunosuppress
medic
primari
agent
use
treatment
sarcoidosi
particularli
gc
often
first
line
agent
littl
known
impact
sarcoidosi
treatment
suscept
diseas
express
infect
howev
lethal
infect
concern
riskbenefit
ratio
effect
immunosuppress
therapi
sarcoidosi
may
alter
current
climat
document
aim
provid
clinician
practic
guidanc
adjust
immunosuppress
therapi
treatment
sarcoidosi
pandem
guidanc
mani
immunosuppress
agent
use
treat
sarcoidosi
use
rheumat
diseas
base
systemat
review
metaanalys
known
drug
notabl
system
gc
biolog
agent
tnf
inhibitor
increas
risk
seriou
infect
tradit
steroidspar
agent
importantli
methotrex
mtx
also
associ
increas
risk
infect
degre
risk
depend
natur
underli
ill
dosag
treatment
durat
infect
question
gener
consid
lower
gc
biolog
agent
although
lower
immunosuppress
might
improv
outcom
sarcoidosi
patient
becom
expos
also
associ
risk
worsen
sarcoidosi
practic
treat
physician
confront
two
gener
scenario
first
patient
clinic
quiescent
maintain
stabl
medic
regimen
second
patient
activ
organthreaten
diseas
stabl
sarcoidosi
patient
receiv
gc
therapi
alon
attempt
made
case
slowli
reduc
corticosteroid
dose
notabl
random
trial
gc
taper
high
proport
patient
treat
placebo
success
abl
taper
prednison
dosag
without
flare
diseas
sever
month
one
studi
patient
pulmonari
sarcoidosi
pulmonari
exacerb
none
receiv
mgday
prednison
time
exacerb
even
exacerb
pulmonari
diseas
usual
result
signific
respiratori
distress
usual
respond
modest
increas
corticosteroid
dosag
week
skin
sarcoidosi
specif
nonlifethreaten
form
diseas
may
prudent
attempt
taper
therapi
stabl
patient
current
diseasemodifi
antisarcoid
drug
dmasd
mtx
mycophenol
mofetil
azathioprin
other
deescal
therapi
consid
achiev
reduc
dose
prolong
dose
interv
exampl
patient
stabl
weekli
mtx
dose
reduct
dose
everi
week
instead
everi
week
reason
option
outright
drug
holiday
sever
week
riskbenefit
continu
reassess
may
consid
patient
could
increas
chanc
abrupt
sarcoidosi
flare
may
refractori
control
prompt
addit
gc
therapi
reemphas
dmasd
may
present
lower
risk
infect
gc
patient
receiv
antimalari
agent
chloroquin
hydroxychloroquin
hcq
suggest
continu
therapi
unfortun
preliminari
inconclus
report
suggest
potenti
benefit
hcq
treatment
widespread
shortag
ensu
patient
receiv
immunosuppress
biolog
agent
may
increas
risk
infect
howev
concern
rebound
sarcoidosi
flare
may
problemat
control
medic
discontinu
abruptli
gradual
dose
reduct
could
consid
exampl
infliximab
ifx
may
given
less
frequent
eg
everi
six
eight
week
instead
monthli
lower
weightbas
dose
eg
mgkg
instead
mgkg
bodi
weight
addit
premed
gc
could
reduc
significantli
elimin
infus
protocol
dmasd
use
prevent
antibodi
format
patient
tnf
inhibitor
low
dose
eg
methotrex
mg
weekli
consid
effect
immunosuppress
reduc
clinician
instruct
sarcoidosi
patient
vigil
chang
condit
suggest
activ
diseas
clinician
establish
facil
method
commun
patient
includ
rapid
consult
system
telemedicin
appropri
safeguard
sarcoidosi
patient
organ
lifethreaten
diseas
signific
dose
reduct
discontinu
therapi
may
contraind
risk
sever
unfavor
outcom
patient
includ
progress
pulmonari
diseas
cardiac
diseas
uveiti
neurosarcoidosi
patient
gc
therapi
alon
manag
lowest
possibl
dose
achiev
diseas
control
highdos
gc
eg
mg
prednison
per
day
necessari
addit
dmasd
may
prudent
enabl
reduct
gc
requir
sinc
gc
therapi
associ
high
risk
infect
sarcoidosi
patient
patient
stabil
dmasd
probabl
maintain
current
dosag
patient
biolog
therapi
ifx
adalimumab
ada
therapi
also
probabl
continu
consequ
diseas
relaps
due
logist
concern
potenti
closur
infus
unit
switch
home
infus
ifx
subcutan
ada
may
consid
care
select
patient
patient
activ
diseas
receiv
biolog
therapi
logist
clinic
reason
altern
treatment
tofacitinib
repositori
corticotropin
other
may
consid
case
case
basi
howev
convinc
evid
efficaci
sever
diseas
clinic
trial
yet
avail
also
suggest
assess
symptom
sarcoidosi
patient
involv
judici
use
object
test
pulmonari
function
test
chest
imag
avoid
unnecessari
evalu
clinic
hospit
standard
practic
emphas
pandem
correl
flare
sarcoidosi
chang
pulmonari
function
chest
imag
known
poor
determin
whether
sarcoidosi
patient
develop
worsen
diseas
may
often
made
clinic
ground
alon
conclus
sarcoidosi
manag
current
pandem
pose
mani
challeng
treat
physician
offer
gener
approach
issu
figur
risk
poor
outcom
infect
must
factor
clinician
treatment
algorithm
may
result
adjust
sarcoidosi
patient
immunosuppress
regimen
depend
stabil
diseas
consequ
diseas
reactiv
immunosuppress
reduc
clearcut
plan
monitor
treat
exacerb
sarcoidosi
place
acknowledg
understand
infect
current
meager
expect
evidencebas
recommend
develop
time
treat
physician
remain
vigil
chang
landscap
avail
test
high
variabl
local
region
preval
viru
evolv
treatment
decis
make
